Twist Bioscience Corporation TWST
Set alert
At close
Pre-market · Nov 2, 7:10 AM ET
- YTD
- +381.65%
- 1 year
- +364.52%
- Open
- 161.39
- Prev close
- 173.45
- Mkt cap
- 10.13B
- Vol
- 3.40M
- Avg vol
- 2.33M
- EPS
- -2.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 148.00
- High
- 167.27
- Forward P/E
- -381.95
- Beta
- 2.19
- Short ratio
- 3.22
- Inst. own
- 116.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 152.78
- 200-d avg
- 88.45
- 1y target
- 168.25
5Y chart
Events in this range
- Aug 4, 2025Earnings: -0.47; estimate -0.54; surprise 12.96%
- Nov 14, 2025Earnings: -0.45; estimate -0.5; surprise 10%
- Feb 2, 2026Earnings: -0.5; estimate -0.48; surprise -4.17%
- May 4, 2026Earnings: -0.71; estimate -0.49; surprise -44.9%
- Aug 3, 2026Earnings: -0.56; estimate -0.50625; surprise -10.62%
- Sep 29, 2026Rating: Leerink Partners · Outperform → Outperform
- Oct 1, 2026Rating: Guggenheim · Buy → Buy
- Oct 7, 2026Rating: Barclays · Overweight → Overweight
- Oct 8, 2026Rating: Jefferies · — → Hold
- Oct 12, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 13, 2026Rating: TD Cowen · Buy → Buy
Signals (98)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| MACD: Sell Signal | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 14, 2026 | 1 month ago |
| RSI: Overbought | Aug 3, 2026 | 3 months ago |
| RSI: Overbought | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| RSI: Overbought | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| RSI: Overbought | Feb 2, 2026 | 9 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 29, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 16, 2025 | 1 year ago |
| SMA: Bearish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 6, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Oct 7, 2024 | 2 years ago |
| SMA: Bearish | Sep 30, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| SMA: Bearish | Sep 2, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| RSI: Overbought | Jul 22, 2024 | 2 years ago |
| MACD: Buy Signal | May 13, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 11, 2024 | 2 years ago |
| RSI: Overbought | Feb 12, 2024 | 2 years ago |
| RSI: Overbought | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 13, 2023 | 2 years ago |
| SMA: Bearish | Nov 6, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 9, 2023 | 3 years ago |
| SMA: Bearish | Oct 2, 2023 | 3 years ago |
| SMA: Bearish | Sep 11, 2023 | 3 years ago |
| SMA: Bullish | Aug 28, 2023 | 3 years ago |
| SMA: Bearish | Aug 14, 2023 | 3 years ago |
| SMA: Bullish | Jun 26, 2023 | 3 years ago |
| SMA: Bullish | May 22, 2023 | 3 years ago |
| MACD: Buy Signal | May 15, 2023 | 3 years ago |
| RSI: Oversold | May 8, 2023 | 3 years ago |
| RSI: Oversold | Apr 24, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Jan 30, 2023 | 3 years ago |
| SMA: Bullish | Jan 16, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 9, 2023 | 3 years ago |
| MACD: Sell Signal | Nov 21, 2022 | 3 years ago |
| SMA: Bearish | Nov 14, 2022 | 3 years ago |
| SMA: Bearish | Nov 14, 2022 | 3 years ago |
| SMA: Bullish | Nov 7, 2022 | 3 years ago |
| SMA: Bullish | Nov 7, 2022 | 3 years ago |
| MACD: Buy Signal | Oct 24, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 17, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| SMA: Bullish | Aug 22, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| SMA: Bearish | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Mar 28, 2022 | 4 years ago |
Key statistics
- Market cap
- 10.13B
- Enterprise value
- 10.82B
- Trailing P/E
- 0.00
- Forward P/E
- -381.95
- PEG ratio
- 0.00
- Price / sales
- 23.46
- Price / book
- 21.48
- EPS (TTM)
- -2.23
- Beta
- 2.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -31.66%
- Revenue (TTM)
- 431.80M
- Revenue growth
- 23.20%
- Free cash flow
- -64.82M
- Total cash
- 166.84M
- Total debt
- 108.59M
- Return on equity
- -29.59%
- Shares outstanding
- 66.30M
- Short % of float
- 19.42%
- 50-day average
- 152.78
- 200-day average
- 88.45
Analyst view
Consensus: buy
- Target (low)
- 45.00
- Target (mean)
- 168.25
- Target (high)
- 215.00
- Strong buy2
- Buy7
- Hold3
- Sell1
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.203.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.38452 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | -0.50625 | -0.56 | -0.05 | -10.62% |
| May 4, 2026 | Mar 31, 2026 | -0.49 | -0.71 | -0.22 | -44.90% |
| Feb 2, 2026 | Dec 31, 2025 | -0.48 | -0.50 | -0.02 | -4.17% |
| Nov 14, 2025 | Sep 30, 2025 | -0.50 | -0.45 | +0.05 | +10.00% |
| Aug 4, 2025 | Jun 30, 2025 | -0.54 | -0.47 | +0.07 | +12.96% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 12, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 8, 2026 | Jefferies | init | — | Hold |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Sep 29, 2026 | Leerink Partners | main | Outperform | Outperform |
About Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- twistbioscience.com
News
- Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
- Parnassus Mid Cap Growth Fund: Q3 2026 Performance Review
- Twist Bioscience Launches MRD Express with Rapid Turnaround Time
- 10 Health Care Stocks Whale Activity In Today’s Session
- Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies
- Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors
- Artisan Mid Cap Fund Q3 2026 Portfolio Update
- TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $190
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205
Your note
Sign in to keep a note on TWST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAN NELSON C | Director | Stock Award(Grant) | Feb 4, 2026 | 33,251 |
| CHESS ROBERT BRUCE | Director | Sale | Aug 6, 2026 | 63,612 |
| CHO DENNIS | Officer | Sale | Oct 1, 2026 | 63,789 |
| CRANDELL KEITH L. | Director | Stock Award(Grant) | Feb 4, 2026 | 103,618 |
| FINN PATRICK JOHN | President | Sale | Oct 22, 2026 | 182,843 |
| GREEN PAULA | Officer | Sale | Oct 1, 2026 | 106,632 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.30% | 5,833,891 | 891.30M | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 7.66% | 4,802,017 | 733.65M | Jun 29, 2026 |
| FMR, LLC | 7.50% | 4,703,044 | 718.53M | Jun 29, 2026 |
| ARK Investment Management, LLC | 7.26% | 4,549,803 | 695.12M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 5.80% | 3,634,652 | 555.30M | Jun 29, 2026 |
| State Street Corporation | 5.15% | 3,232,532 | 493.87M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 1,874,473 | 286.38M | Jun 29, 2026 |
| ARK ETF Trust-ARK Innovation ETF | 2.95% | 1,847,954 | 282.33M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.73% | 1,714,174 | 261.89M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 1,357,205 | 207.35M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.92% | 1,201,502 | 183.57M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.88% | 1,177,281 | 179.86M | Sep 29, 2026 |